3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Research Precision

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a highly potent inhibitor of poly (ADP-ribose) polymerase (PARP) with an IC₅₀ of approximately 50 nM in CHO cells, showing >95% inhibition of PARP activity at concentrations above 1 μM with minimal cytotoxicity (APExBIO). It mediates protection against oxidant-induced myocyte dysfunction and improves nitric oxide-mediated vasorelaxation after oxidative stress (Grunewald et al., 2019). In diabetic db/db mouse models, it reduces albumin excretion and ameliorates podocyte depletion, highlighting its translational utility in diabetic nephropathy research (APExBIO). Its robust solubility and storage profile facilitate experimental reproducibility. The compound is strictly for research use, not for diagnostic or therapeutic purposes.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes responsible for the post-translational modification of proteins via ADP-ribosylation, using NAD⁺ as a substrate. This modification regulates DNA repair, cellular stress responses, and antiviral defense mechanisms (Grunewald et al., 2019). Human cells encode at least 17 PARP isoforms, with PARP1 and PARP2 playing prominent roles in DNA repair (Grunewald et al., 2019). Inhibition of PARP activity can modulate cellular processes such as DNA damage response and inflammation. As a result, potent and selective PARP inhibitors are indispensable tools for dissecting PARP-mediated pathways in cellular and disease models.

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide (PARP-IN-1) acts as a competitive inhibitor of the PARP enzyme family by mimicking the nicotinamide moiety of NAD⁺. It binds to the catalytic domain of PARP1 and PARP2, preventing the transfer of ADP-ribose units to target proteins (Grunewald et al., 2019). This inhibition results in reduced poly (ADP-ribosyl)ation activity, leading to altered DNA repair dynamics and modulation of cell survival pathways. At concentrations above 1 μM, 3-Aminobenzamide achieves >95% inhibition of PARP activity in CHO cells without significant cytotoxicity (APExBIO).

Evidence & Benchmarks

• 3-Aminobenzamide exhibits a PARP inhibition IC₅₀ of ~50 nM in CHO cell assays (APExBIO product data).
• At >1 μM, it achieves more than 95% inhibition of PARP activity without significant cytotoxicity (APExBIO).
• PARP inhibition by 3-Aminobenzamide mediates protection against oxidant-induced myocyte dysfunction during reperfusion (Grunewald et al., 2019).
• Enhances acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation after H₂O₂-induced oxidative stress (Grunewald et al., 2019).
• In diabetic db/db mouse models, reduces albumin excretion, mesangial expansion, and podocyte depletion, supporting its use in diabetic nephropathy research (APExBIO).
• Demonstrated effects on ADP-ribosylation-dependent antiviral responses in murine models, supporting broad utility in infection research (Grunewald et al., 2019).

This article extends the practical workflow recommendations found in "Scenario-Based Best Practices with 3-Aminobenzamide (PARP-IN-1)" by providing new evidence on disease-specific endpoints and clarifying mechanistic boundaries. For a deeper mechanistic and translational perspective, see "3-Aminobenzamide (PARP-IN-1): Precision PARP Inhibition for Translational Research", which this dossier updates with recent antiviral findings. Additionally, the current article synthesizes and benchmarks outcomes reported in "3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Precision Biology" with more refined subcellular and disease model data.

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is widely used in research settings to dissect the role of PARP in DNA repair, oxidative stress, and inflammation. Its use extends to studies on diabetic nephropathy, where it ameliorates disease phenotypes in animal models. The compound has also been leveraged in studies investigating the interplay between PARP activity and viral replication, as in the context of coronavirus infection (Grunewald et al., 2019).

Common Pitfalls or Misconceptions

• 3-Aminobenzamide is not suitable for diagnostic or clinical therapeutic applications; it is for research use only (APExBIO).
• It is not selective for a single PARP isoform and may impact multiple PARP family members, necessitating proper control experiments (Grunewald et al., 2019).
• Long-term storage of solutions is not recommended due to compound instability; fresh solutions should be prepared for each experiment (APExBIO).
• Some cellular models may exhibit off-target effects at high concentrations; dose titration is recommended (internal dossier).

Workflow Integration & Parameters

3-Aminobenzamide (PARP-IN-1) is supplied as a solid with a molecular weight of 136.15 g/mol and chemical formula C₇H₈N₂O. It is soluble at ≥23.45 mg/mL in water, ≥48.1 mg/mL in ethanol, and ≥7.35 mg/mL in DMSO with ultrasonic assistance (APExBIO). For optimal stability, store at -20°C and avoid long-term storage of solutions. Shipping is performed on Blue Ice for small molecules. When integrating into PARP activity inhibition assays, researchers should ensure precise dosing and include appropriate controls for off-target PARP family inhibition. Its robust solubility profile enables use in a variety of in vitro and in vivo models. For detailed scenario-based best practices, refer to "Scenario-Based Best Practices with 3-Aminobenzamide (PARP-IN-1)".

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1), available from APExBIO, remains a gold-standard tool compound for dissecting the biological functions of PARP enzymes. Its nanomolar potency, low toxicity, and well-characterized action profile make it essential in research on DNA repair, oxidative stress, and disease models such as diabetic nephropathy. Ongoing studies continue to reveal new mechanistic insights and translational opportunities, particularly at the interface of immunology and virology. For further product details and ordering information, visit the 3-Aminobenzamide (PARP-IN-1) product page.